'''钠-葡萄糖协同转运蛋白2抑制剂'''（{{lang-en|'''SGLT2 inhibitors'''}}，简称'''SGLT2抑制剂'''，或称'''列净类药物'''（{{lang-en|'''Gliflozin'''}}））是一种通过[[受体拮抗剂|抑制]][[葡萄糖|葡萄糖]]在[[肾脏|肾脏]]内[[重吸收|重吸收]]而起到降糖作用的[[抗糖尿病药|抗糖尿病药]]。<ref name=Shubrook2015>{{cite journal|last1=Shubrook|first1=Jay H|last2=Bokaie|first2=Babak Baradar|last3=Adkins|first3=Sarah E|title=Empagliflozin in the treatment of type 2 diabetes: evidence to date|journal=Drug design, development and therapy|date=October 2015|volume=9|pages=5793–803|doi=10.2147/DDDT.S69926|pmid=26586935|pmc=4634822|type=Review}}</ref> 其原理为抑制[[钠-葡萄糖协同转运蛋白2|钠-葡萄糖协同转运蛋白2]]，用来治疗[[2型糖尿病|2型糖尿病]]。根据对[[坎格列净|坎格列净]]（Canagliflozin）的研究，SGLT2抑制剂可以降低[[血糖水平|血糖水平]]和[[体重|体重]]，并且可以降低[[血压|舒张压]]与[[血压|收缩压]]。 <ref name="HaasEckstein2014">{{cite journal|last1=Haas|first1=B|last2=Eckstein|first2=N|last3=Pfeifer|first3=V|last4=Mayer|first4=P|last5=Hass|first5=M D S|title=Efficacy, safety and regulatory status of SGLT2 inhibitors: focus on canagliflozin|journal=Nutrition & Diabetes|volume=4|issue=11|year=2014|pages=e143|issn=2044-4052|doi=10.1038/nutd.2014.40|pmid=25365416}}</ref>

==药物列表==
数种药物已被开发或者正在进行临床试验，它们包括：<ref>{{cite web |url=http://www.insightpharmareports.com/uploadedFiles/ExecutiveSummary.pdf |title=Diabetes Pipeline: Intense Activity to Meet Unmet Need |year=2010 |author=InsightPharma |page=vii }}</ref>

* [[达格列净|达格列净]]（Dapagliflozin），由[[阿斯利康|阿斯利康]]研发，是第一种获批的SGLT2抑制剂，[[欧盟|欧盟]]在2011年首先批准了此药物。2014年[[FDA|FDA]]批准其在美国销售。<ref>{{cite web|last1=Liscinsky|first1=Morgan|title=FDA approves Farxiga to treat type 2 diabetes|url=http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm380829.htm|publisher=U.S. Food and Drug Administration|accessdate=15 April 2015|date=Jan 8, 2014}}</ref>
* [[恩格列净|恩格列净]]（Empagliflozin）, 由[[勃林格殷格翰|勃林格殷格翰]]研发，2014年获FDA批准，是目前对SGLT2选择性最强的药物。<ref>{{cite news|title=FDA approves Jardiance® (empagliflozin) tablets for adults with type 2 diabetes|url=http://us.boehringer-ingelheim.com/news_events/press_releases/press_release_archive/2014/08-01-14-fda-approves-jardiance-empagliflozin-tablets-reduce-blood-sugar-levels-adults-type-2-diabetes.html|accessdate=5 November 2014|publisher=Boehringer Ingelheim /  Eli Lilly and Company|date=1 August 2014|deadurl=yes|archiveurl=https://web.archive.org/web/20141105201008/http://us.boehringer-ingelheim.com/news_events/press_releases/press_release_archive/2014/08-01-14-fda-approves-jardiance-empagliflozin-tablets-reduce-blood-sugar-levels-adults-type-2-diabetes.html|archivedate=5 十一月 2014}}</ref> <ref name=Shubrook2015/><ref>Goldenberg R, et al. Can J Diabetes. 2016;40:193-195.</ref>
* [[坎格列净|坎格列净]]（Canagliflozin）, 由[[强生公司|强生公司]]旗下的[[田边三菱制药|田边三菱制药]]研发，是第一种在美国获批的SGLT2抑制剂，随后欧盟也批准其销售。<ref>[http://www.empr.com/invokana-first-in-new-class-of-diabetes-drugs-approved/article/286736/ Invokana, First in New Class of Diabetes Drugs, Approved], ''MPR'', March 29, 2013</ref> 坎格列汀可同时抑制SGLT1和SGLT2。<ref name=Shubrook2015/>
* [[Ipragliflozin|Ipragliflozin]] (ASP-1941)，由日本[[安斯泰来|安斯泰来]]制药研发，2014年在日本获批。 .<ref name=pharma-share>[http://www.pharma-share.com/sglt-2-inhibitor-approval-race-%E2%80%93-astrazeneca-bristol-myers-squibb-home-gold-dapagliflozin SGLT2 inhibitor approval race] {{Wayback|url=http://www.pharma-share.com/sglt-2-inhibitor-approval-race-%E2%80%93-astrazeneca-bristol-myers-squibb-home-gold-dapagliflozin |date=20150604221043 }}</ref><ref>{{cite web|title=Approval of Suglat® Tablets, a Selective SGLT2 Inhibitor for Treatment of Type 2 Diabetes, in Japan|url=http://www.astellas.com/en/corporate/news/detail/approval-of-suglat-tablets-a-s.html|date=January 17, 2014}}</ref>
* [[Tofogliflozin|Tofogliflozin]]，由[[赛诺菲|赛诺菲]]和[[武田制药|武田制药]]研发，已在日本获批。<ref>{{cite journal|last1=Poole|first1=RM|last2=Prossler|first2=JE|title=Tofogliflozin: first global approval|journal=Drugs|date=Jun 2014|volume=74|issue=8|pages=939–44|doi=10.1007/s40265-014-0229-1|pmid=24848755}}</ref>
* [[Sergliflozin_etabonate|Sergliflozin etabonate]]，研发中止于二期[[临床试验|临床试验]]。

== 作用机理 ==
[[File:Kidney_Nephron.png|thumb]]

==引用==
{{reflist}}

{{Oral_hypoglycemics}}

[[Category:糖尿病药物|Category:糖尿病药物]]
[[Category:SGLT2抑制剂|]]